CoChat

Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

The innate immune system plays a major role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Recently we reported complement activation in human NASH. However, it remained unclear whether the alternative pathway of complement, which amplifies C3 activation and which is frequently associated with pathological complement activation leading to disease, was involved. Here, alternative pathway components were investigated in liver biopsies of obese subjects with healthy livers (n = 10) or with NASH (n = 12) using quantitative PCR, Western blotting, and immunofluorescence staining. Properdin accumulated in areas where neutrophils surrounded steatotic hepatocytes, and colocalized with the C3 activation product C3c. C3 activation status as expressed by the C3c/native C3 ratio was 2.6-fold higher (p<0.01) in subjects with NASH despite reduced native C3 concentrations (0.94±0.12 vs. 0.57±0.09; p<0.01). Hepatic properdin levels positively correlated with levels of C3c (rs = 0.69; p<0.05) and C3c/C3 activation ratio (rs = 0.59; p<0.05). C3c, C3 activation status (C3c/C3 ratio) and properdin levels increased with higher lobular inflammation scores as determined according to the Kleiner classification (C3c: p<0.01, C3c/C3 ratio: p<0.05, properdin: p<0.05). Hepatic mRNA expression of factor B and factor D did not differ between subjects with healthy livers and subjects with NASH (factor B: 1.00±0.19 vs. 0.71±0.07, p = 0.26; factor D: 1.00±0.21 vs. 0.66±0.14, p = 0.29;). Hepatic mRNA and protein levels of Decay Accelerating Factor tended to be increased in subjects with NASH (mRNA: 1.00±0.14 vs. 2.37±0.72; p = 0.22; protein: 0.51±0.11 vs. 1.97±0.67; p = 0.28). In contrast, factor H mRNA was downregulated in patients with NASH (1.00±0.09 vs. 0.71±0.06; p<0.05) and a similar trend was observed with hepatic protein levels (1.12±0.16 vs. 0.78±0.07; p = 0.08). Collectively, these data suggest a role for alternative pathway activation in driving hepatic inflammation in NASH. Therefore, alternative pathway factors may be considered attractive targets for treating NASH by inhibiting complement activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0110053

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Alternative pathway related factors in NASH. A) Hepatic properdin protein levels were not significantly different between subjects with a healthy liver and subjects with NASH (p = 0.92). B) Representative images of immunofluorescent stainings for properdin (green) and myeloperoxidase (MPO, red), showing pronounced extracellular accumulation of properdin in areas where neutrophils surround steatotic hepatocytes in subjects with NASH (100× magnification), whereas control subjects with healthy livers display no or little properdin accumulation and neutrophil infiltration (100× magnification). C) Quantitative analysis of immunofluorescent staining for MPO+ cells (***p<0.001) and properdin+/MPO+ cells (***p<0.001) in healthy livers and livers from subjects with NASH. D) Hepatic factor B mRNA expression was comparable in subjects with healthy livers and subjects with NASH (p = 0.26). E) Similar mRNA expression of factor D in the study groups (p = 0.29).
Figure 1 Alternative pathway related factors in NASH. A) Hepatic properdin protein levels were not significantly different between subjects with a healthy liver and subjects with NASH (p = 0.92). B) Representative images of immunofluorescent stainings for properdin (green) and myeloperoxidase (MPO, red), showing pronounced extracellular accumulation of properdin in areas where neutrophils surround steatotic hepatocytes in subjects with NASH (100× magnification), whereas control subjects with healthy livers display no or little properdin accumulation and neutrophil infiltration (100× magnification). C) Quantitative analysis of immunofluorescent staining for MPO+ cells (***p<0.001) and properdin+/MPO+ cells (***p<0.001) in healthy livers and livers from subjects with NASH. D) Hepatic factor B mRNA expression was comparable in subjects with healthy livers and subjects with NASH (p = 0.26). E) Similar mRNA expression of factor D in the study groups (p = 0.29).CC BY · PubMed Central
Figure 2 C3 activation in human NASH. A) Semi-quantitative analysis of Western blot (see 2B) for hepatic protein C3c levels in subjects with NASH and subjects with healthy livers (p = 0.24). B) Western blot showing a clear shift from the native C3 band towards the smaller C3c band in subjects with NASH (see arrows). In contrast, healthy subjects showed high concentrations of native C3 and low levels of C3c (see arrows). C) Semi-quantitative analysis of Western blots confirmed significantly lower levels of native C3 protein in the liver of subjects with NASH (*p<0.05). D) The ratio of C3c/native C3, reflecting the activation status of C3, was higher in subjects with NASH compared to controls (**p<0.01). E) Decreased hepatic C3 mRNA expression in subjects with NASH compared to control subjects (*p<0.05). F) In subjects with NASH, hepatic properdin protein expression levels correlated significantly with C3c protein levels (rs = 0.69; *p<0.05). G) A similar correlation in subjects with NASH was observed between properdin and the C3c/native C3 ratio (rs = 0.59; *p<0.05). H) Representative image of immunofluorescent stainings for properdin (green) and C3c (red), showing pronounced colocalization of properdin and C3 activation (C3c) in areas with steatotic hepatocytes in subjects with NASH.
Figure 2 C3 activation in human NASH. A) Semi-quantitative analysis of Western blot (see 2B) for hepatic protein C3c levels in subjects with NASH and subjects with healthy livers (p = 0.24). B) Western blot showing a clear shift from the native C3 band towards the smaller C3c band in subjects with NASH (see arrows). In contrast, healthy subjects showed high concentrations of native C3 and low levels of C3c (see arrows). C) Semi-quantitative analysis of Western blots confirmed significantly lower levels of native C3 protein in the liver of subjects with NASH (*p<0.05). D) The ratio of C3c/native C3, reflecting the activation status of C3, was higher in subjects with NASH compared to controls (**p<0.01). E) Decreased hepatic C3 mRNA expression in subjects with NASH compared to control subjects (*p<0.05). F) In subjects with NASH, hepatic properdin protein expression levels correlated significantly with C3c protein levels (rs = 0.69; *p<0.05). G) A similar correlation in subjects with NASH was observed between properdin and the C3c/native C3 ratio (rs = 0.59; *p<0.05). H) Representative image of immunofluorescent stainings for properdin (green) and C3c (red), showing pronounced colocalization of properdin and C3 activation (C3c) in areas with steatotic hepatocytes in subjects with NASH.CC BY · PubMed Central
Figure 3 Alterations in regulators of the alternative pathway in human NASH. A) Reduced factor H mRNA expression in the liver of subjects with NASH compared to subjects with healthy livers (*p<0.05). B) Semi-quantitative analysis of hepatic factor H protein levels (p = 0.08). C) Correlation between hepatic factor H and hepatic properdin protein levels in subjects with NASH (rs = 0.56; p = 0.08). D) Hepatic DAF mRNA expression in patients with NASH compared to controls (p = 0.22). E) The increase in hepatic DAF protein levels in subjects with NASH was not statistically significant (p = 0.28). F) However, there was a significant correlation between hepatic DAF protein levels and the activation ratio of C3c/native C3 in subjects with NASH (rs = 0.73; **p<0.01).
Figure 3 Alterations in regulators of the alternative pathway in human NASH. A) Reduced factor H mRNA expression in the liver of subjects with NASH compared to subjects with healthy livers (*p<0.05). B) Semi-quantitative analysis of hepatic factor H protein levels (p = 0.08). C) Correlation between hepatic factor H and hepatic properdin protein levels in subjects with NASH (rs = 0.56; p = 0.08). D) Hepatic DAF mRNA expression in patients with NASH compared to controls (p = 0.22). E) The increase in hepatic DAF protein levels in subjects with NASH was not statistically significant (p = 0.28). F) However, there was a significant correlation between hepatic DAF protein levels and the activation ratio of C3c/native C3 in subjects with NASH (rs = 0.73; **p<0.01).CC BY · PubMed Central
Figure 4 Association between properdin, DAF, and C3c with hepatic steatosis and inflammation. A) C3c levels in the liver were not different (p = 0.27) between subjects with grade 2 steatosis (N = 5) and subjects with grade 3 steatosis (N = 7). B) Levels of hepatic properdin were not related to the grade of steatosis (p = 0.27). C) Progressively increasing levels of hepatic C3c with higher lobular inflammation scores (**p<0.01). D) Hepatic C3 activation (C3c/native C3 ratio) was increased in subjects with highest lobular inflammation scores (**p<0.01). E) Gradually increasing hepatic properdin protein concentrations in subjects with higher lobular inflammation scores (*p<0.05). F) No correlation was observed between hepatic DAF protein levels and NAS score (rs = 0.30; p = 0.34). G) Hepatic C3c protein levels were significantly correlated with NAS score in patients with NASH (rs = 0.63; *p<0.05). H) A similar, but not significant correlation was observed between the C3c/native C3 activation ratio and NAS score (rs = 0.51; p = 0.09). I) Hepatic Properdin protein levels did not correlated with NAS score (rs = 0.42; p = 0.17).
Figure 4 Association between properdin, DAF, and C3c with hepatic steatosis and inflammation. A) C3c levels in the liver were not different (p = 0.27) between subjects with grade 2 steatosis (N = 5) and subjects with grade 3 steatosis (N = 7). B) Levels of hepatic properdin were not related to the grade of steatosis (p = 0.27). C) Progressively increasing levels of hepatic C3c with higher lobular inflammation scores (**p<0.01). D) Hepatic C3 activation (C3c/native C3 ratio) was increased in subjects with highest lobular inflammation scores (**p<0.01). E) Gradually increasing hepatic properdin protein concentrations in subjects with higher lobular inflammation scores (*p<0.05). F) No correlation was observed between hepatic DAF protein levels and NAS score (rs = 0.30; p = 0.34). G) Hepatic C3c protein levels were significantly correlated with NAS score in patients with NASH (rs = 0.63; *p<0.05). H) A similar, but not significant correlation was observed between the C3c/native C3 activation ratio and NAS score (rs = 0.51; p = 0.09). I) Hepatic Properdin protein levels did not correlated with NAS score (rs = 0.42; p = 0.17).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 52

Metadata

Authors
Segers, F. M., Verdam, F. J., de Jonge, C., Boonen, B., Driessen, A., Shiri-Sverdlov, R., Bouvy, N. D., Greve, J. W. M., Buurman, W. A., & Rensen, S. S.
Affiliations
  • Maastricht University Medical Centre (NL)
  • Atrium Medisch Centrum Parkstad (NL)
Corresponding author
Rensen, Sander S.
Venue
PLoS ONE
Published
2014-10-09
Volume
9
Issue
10
Pages
e110053
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2008456888
Cited by
50
References
40
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 1
FWCI
1.76
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, cc-by)
Funders
  • Rijksdienst voor Ondernemend Nederland
  • Transnationale Universiteit Limburg
  • SenterNovem
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
nonalcoholic steatohepatitis, alternative complement pathway, properdin, C3 activation, C3c, CD55, complement factor H, factor B, factor D, liver inflammation, innate immunity, hepatic steatosis, obesity, neutrophils
MeSH terms
Adult, Biopsy, Complement Pathway, Alternative, Complement C3, Gene Expression Regulation, Humans, Inflammation, Liver, Properdin, Complement Factor B, Complement Factor D, RNA, Messenger, Complement Factor H, Complement C3-C5 Convertases, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.1371/journal.pone.0110053
The paper
Segers, F. M., Verdam, F. J., de Jonge, C., Boonen, B., Driessen, A., Shiri-Sverdlov, R., Bouvy, N. D., Greve, J. W. M., Buurman, W. A., & Rensen, S. S. (2014). Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis. PLoS ONE. https://doi.org/10.1371/journal.pone.0110053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.